|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Multiple Sclerosis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Sclerosis | |||||
| 3 | More general conditions related to this trial | ||||
| Autoimmune Diseases | |||||
| Autoimmune Diseases of the Nervous System | |||||
| Demyelinating Autoimmune Diseases, CNS | |||||
| Demyelinating Diseases | |||||
| Immune System Diseases | |||||
| Nervous System Diseases | |||||
| Pathologic Processes | |||||
| 4 | Interventions listed in this trial | ||||
| Rolipram | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antidepressive Agents | |||||
| Central Nervous System Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Phosphodiesterase Inhibitors | |||||
| Psychotropic Drugs | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute of Neurological Disorders and Stroke (NINDS) | |||||